LONG MINI-FUTURE - GENMAB | Real-time Boerse Frankfurt Warrants 07:44:11 2024-07-03 am EDT | ||
| 2.97 EUR | +8.39% |
|
| Current month | -11.33% | ||
| 1 month | -52.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 2.97 | +8.39% |
| 24-07-02 | 2.74 | -8.05% |
| 24-07-01 | 2.98 | -3.56% |
| 24-06-28 | 3.09 | -16.26% |
| 24-06-27 | 3.69 | -1.34% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 07:44 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP1SU7 |
| ISIN | DE000VP1SU77 |
| Date issued | 2020-03-25 |
| Strike | 1,511 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.36 € |
|---|---|
| Lowest since issue | 0.9 € |
| Spread | 0.02 € |
| Spread % | 0.66% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,720
DKK
Average target price
2,464
DKK
Spread / Average Target
+43.30%
- Stock Market
- Certificates
- Certificat
